BACKGROUND: A post-authorisation safety study (PASS) on delamanid (DLM) was conducted as part of a post-approval commitment to the European Medicines Agency. The aim of this study was to evaluate the use of DLM in a real-life setting. its safety. and treatment outcomes in patients with multidrug-resistant TB (MDR-TB). https://www.thebrickes.shop/product-category/tent-accessories/